ascopubs.org

Characterizing differential efficacy and phenotypic response to proteasome and survivin inhibitors in colorectal cancers using a high throughput organoid assay.

Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER ...
ascopubs.org

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.

Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response. mCBR duration in months (IQR) 5.4 (4.2−9.9) 8.1 (6.3−10.8) 6.9 (5.4−10.3) ...